First orders for dental and nerve products 

27 September 2022
Posted in Company News
27 September 2022 Orthocell

Orthocell has now received first purchase orders for our flagship collagen medical device products Striate+™ and Remplir, via our valued distribution partners.

This commercial milestone follows Orthocell’s recent exclusive global licence and distribution deal with BioHorizons Implant Systems Inc. (BioHorizons) for Striate+™, and exclusive Australian distribution agreement with Device Technologies (DVT) for Remplir™ – both defining achievements for our growing Company.

Click here to view today’s ASX release.